ÂÜÀòÂÒÂ×

Sam Fazeli has served as a member of the Arecor Board of Directors since September 2017 and brings over twenty-two years of experience of conducting equity research as a pharmaceutical analyst, working at firms including Nomura International and HSBC. Currently, he is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.

Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by both the UK and Pan-European Extel surveys.

He holds a degree from Cardiff University, and a Ph.D. in pharmacology from the University of London.